Stock Taper
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Biohaven's leading investigational drug for Spinocerebellar Ataxia (SCA), a rare neurological disorder, is a top pipeline candidate with a resubmitted FDA New Drug Application, highlighting its primary therapeutic focus.
| Icon | PRODUCT | Q1-2022 | Q2-2022 |
|---|---|---|---|
![]() | Collaboration And Other | $195.26M | — |
![]() | Product | $123.59M | $193.95M ▲ |
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
ABCL | $11.35 | COMPARE |
IMNM | $27.57 | COMPARE |
CLDX | $39.12 | COMPARE |
PHVS | $35.32 | COMPARE |
VERA | $34.19 | COMPARE |
ZBIO | $31.27 | COMPARE |
IMCR | $36.62 | COMPARE |
NTLA | $12.87 | COMPARE |